Letters sent to healthcare professionals in November 2015

In November, letters were sent regarding thalidomide, mycophenolate mofetil, nicorandil, InductOs, and dimethyl fumarate

• From: Medicines and Healthcare products Regulatory Agency
• Published: 14 December 2015
• Last updated: 14 December 2015 — See all updates

• Therapeutic area: Cancer, Cardiovascular disease and lipidology, GI, hepatology and pancreatic disorders, Haematology, Immunosuppression and transplantation, Neurology and Obstetrics, gynaecology and fertility

A summary of letters sent to healthcare professionals in November 2015 to inform of safety for:

• Thalidomide (Thalidomide Celgene): reduced starting dose in patients older than age 75 years (see also this month’s article)
• Mycophenolate mofetil (CellCept): pregnancy-prevention advice (see also this month’s article)
• Nicorandil (Ikorel): second-line treatment for angina; risk of progressive ulceration
• .InductOs: supply shortage
• Dimethyl fumarate (Tecfidera): new measures to minimise the risk of progressive multifocal leukoencephalopathy

Published 14 December 2015
Last updated 14 December 2015 + show all updates

1. 14 December 2015

   Letters sent to healthcare professionals in November 2015

2. 14 December 2015

   First published.